Insider at

04

Insider transactions

05
0 buys (P) 3 sells (S) Net: $-240,431 + 20 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

20 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Aug. 17, 2026 PCRX S 10b5-1 3,040 $23.23 $70,619 216,384 Direct -1.39% Disposed 8.5% (price as of 2026-10-02)
March 17, 2026 PCRX S 10b5-1 3,261 $22.82 $74,416 223,640 Direct -1.44% Disposed 10.5% (price as of 2026-10-02)
Nov. 17, 2025 PCRX S 10b5-1 3,960 $24.09 $95,396 178,367 Direct -2.17% Disposed 4.6% (price as of 2026-10-02)
Jan. 6, 2025 PCRX S 10b5-1 879 $18.40 $16,174 93,444 Direct -0.93% Disposed 37.0% (price as of 2026-10-02)
Aug. 2, 2024 PCRX S 10b5-1 945 $20.05 $18,947 94,307 Direct -0.99% Disposed 25.7% (price as of 2026-10-02)
July 2, 2024 PCRX S 10b5-1 2,836 $28.25 $80,117 95,557 Direct -2.88% Disposed -10.8% (price as of 2026-10-02)
June 11, 2024 PCRX S 10b5-1 5,012 $28.57 $143,193 44,569 Direct -10.11% Disposed -11.8% (price as of 2026-10-02)
June 7, 2023 PCRX S 490 $37.86 $18,551 36,323 Direct -1.33% Disposed -33.4% (price as of 2026-10-02)
June 6, 2023 PCRX S 471 $38.99 $18,364 36,813 Direct -1.26% Disposed -35.3% (price as of 2026-10-02)
Aug. 3, 2022 PCRX S 308 $55.70 $17,156 37,079 Direct -0.82% Disposed -54.7% (price as of 2026-10-02)
July 5, 2022 PCRX S 924 $57.19 $52,844 37,387 Direct -2.41% Disposed -55.9% (price as of 2026-10-02)
June 8, 2022 PCRX S 24,800 · · 24,800 Direct · Acquired (price as of 2026-10-02)
June 6, 2022 PCRX S 362 $61.37 $22,216 28,197 Direct -1.27% Disposed -58.9% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Jan. 3, 2024 PCRX Stock Option (Right to Buy) Common Stock (10,000) $32.07 Jan. 3, 2034 10,000 Acquired
June 8, 2022 PCRX Stock Option (Right to Buy) Common Stock (24,800) $59.39 June 8, 2032 24,800 Acquired
May 23, 2022 PCRX Stock Option (Right to Buy) Common Stock (2,000) $52.37 July 2, 2030 2,000 Disposed
Aug. 3, 2021 PCRX Stock Option (Right to Buy) Common Stock (10,000) $60.79 July 20, 2031 10,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 9 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Dec. 7, 2023 PCRX Common Stock 45,884 Direct
Dec. 7, 2023 PCRX Stock Option (Right to Buy)→ Common Stock (27,500) 27,500 Direct
Dec. 7, 2023 PCRX Stock Option (Right to Buy)→ Common Stock (24,800) 24,800 Direct
Dec. 7, 2023 PCRX Stock Option (Right to Buy)→ Common Stock (10,000) 10,000 Direct
Dec. 7, 2023 PCRX Stock Option (Right to Buy)→ Common Stock (14,137) 14,137 Direct
Dec. 7, 2023 PCRX Stock Option (Right to Buy)→ Common Stock (35,500) 35,500 Direct
July 30, 2021 PCRX Common Stock 21,350 Direct
July 30, 2021 PCRX Stock Option (Right to Buy)→ Common Stock (14,137) 14,137 Direct
July 30, 2021 PCRX Stock Option (Right to Buy)→ Common Stock (37,500) 37,500 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

PCRX

Chief Medical Officer
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2023 $490,225 $220,300 $424,203 $438,138 · · $20,347 $1,593,213
2022 $463,500 $185,400 $587,961 $621,240 · · $20,933 $1,879,034

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.